Hepatoprotective Effects of Liv.52 in Chronic Liver Disease Preclinical, Clinical, and Safety Evidence: A Review

Chronic liver disease (CLD) is a growing concern worldwide. The common etiological factors include infection, alcohol abuse, exposure to hepatotoxic drugs, autoimmune disorders, and metabolic diseases. The chronic liver disease progresses to liver cirrhosis and its consequent complications. It is routinely managed by a combination of various therapies in combination with lifestyle modifications. The current literature supports the growing importance of the usage of herbal medicines in the management of CLD due to their efficacy and very low incidence of adverse effects. Liv.52 is a known polyherbal formulation and has been used for over 50 years in India and other countries. The evidence collected from preclinical and clinical studies supports the use of Liv.52 in symptomatic improvement and supportive treatment due to hepatitis (including Hepatitis B), alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH) and hepatotoxicity due to drugs used in the treatment of tuberculosis. Liv.52 has also shown some preliminary hepatoprotective effects in patients with liver cirrhosis due to its potential antioxidant and anti-inflammatory effects. Both the syrup and tablet formulations are well tolerated and have shown a good safety profile. Liv.52 may be a favorable herbal choice for the management of CLD due to various etiologies.